

Date of Document: May 23, 2021

## CURRICULUM VITAE

*Russell Edward Scheffer, M.D.*  
Cigna Medical Director  
*Benton, Kansas*

1. **Home Address:** 4600 SW Prairie Creek Rd.  
Benton, KS 67017
2. **Office Address:** Cigna  
4600 SW Prairie Creek Rd.  
Benton, KS 67017
3. **Place of Birth:** Aurora, Colorado
4. **Citizenship:** U.S.A.
5. **Education:**

08/1981-12/1982	Biology and Chemistry, University of Nebraska, Lincoln, NB
07/1983-05/1985	Chemistry, United States Military Academy, West Point, NY
08/1985-05/1987	B.S., Human Biology, University of Kansas, Lawrence, KS
08/1987-05/1991	M.D., Kansas University Medical Center Kansas City, Kansas
6. **Postgraduate Training and Fellowship Training:**

07/1991-06/1995	Intern and Resident, General Psychiatry Dwight David Eisenhower Army Medical Center. Fort Gordon, Georgia 30905
07/1995-06/1996	Child, Adolescent and Family Psychiatry Fellowship DDEAMC/Medical College of Georgia Combined Program Augusta, Georgia 30912
07/1992-06/1996	Research Fellowship Training: The Psychobiology of Psychotic Illnesses. Medical College of Georgia, Augusta, Georgia 30912. Mentors: Dr. Sukdeb Mukherjee, M.D. and Dr. Sahebarao Mahadik, Ph.D.

7. **Military Service:**
- |                 |  |
|-----------------|--|
| 07/1983-05/1985 | United States Military Academy, West Point, NY             |
| 08/1987-05/1991 | U.S. Army Reserves, Health Professions Scholarship Program |
| 05/1991-06/2000 | U.S. Army Medical Department Active Duty                   |

U.S. Army Medical Department Awards:

Army Commendation Award  
Army Achievement Award  
Army Superior Unit Award  
Cold War Victory Award

8. **Academic Appointments:**

- |                 |   |
|-----------------|---|
| 05/1996–06/2002 | Assistant Clinical Professor of Psychiatry (While a full time active duty medical officer). Medical College of Georgia. Augusta, GA 30912.    |
| 07/1996-06/1998 | Assistant Professor of Psychiatry (While a full time active duty medical officer at Darnall ACH) Texas A&M Health Science Center, Temple, TX. |
| 06/2000-06/2003 | Assistant Professor of Psychiatry<br>UT Southwestern Medical Center, Dallas, TX   |
| 07/2003–06/2007 | Associate Professor of Psychiatry and Pediatrics<br>Medical College of Wisconsin, Milwaukee, WI   |
| 2005-2013       | Affiliated Investigator Center for the Study of Cultural Diversity in Healthcare University of Wisconsin, Madison                             |
| 06/2007-06/2014 | Professor with Tenure, Psychiatry and Behavioral Sciences and Pediatrics<br>Kansas University School of Medicine-Wichita                      |
| 07/2014-05/2016 | Clinical Professor of Psychiatry and Pediatrics<br>Kansas University School of Medicine-Wichita   |

9. **Administrative Appointments:**

Cigna Healthcare:

- |                 |  |
|-----------------|--|
| 05/2016-present | Medical Director, Cigna Behavioral Healthcare<br>General Psychiatry Clinical Rounds Leader |
| 06/2017-present | Transcranial Magnetic Stimulation Committee<br>Veteran ERG at Cigna. Member                |
| 12/2018-present | Interrater Reliability Co-Chair Behavioral health care                                     |
| 01/2019-present | Cigna Health Care.<br>Interrater Reliability Committee Member                              |
| 01/2019-present | ABLE ERG at Cigna. Member  |
| 06/2019-present | Clinical Performance & Quality Committee   |
| 08/2019-present | Autism Rounds Leader<br>Credentialing Committee<br>Credentialing Committee Chair           |

06/2007-Feb 2012	Chair, Department of Psychiatry and Behavioral Sciences Kansas University School of Medicine-Wichita
06/2010-2016	CEO, Kansas Neuroscience, LLC Principal Investigator 1010 N. Kansas, Wichita, KS 67214
12/2009-2012	CEO, Clinical Research Institute, LLC 201 S. Hillside Wichita, KS 67211
2008-2013	Principal Investigator, Clinical Research Institute 1010 N Kansas Wichita, KS 67211
07/2003-06/2007	Division Director, Child and Adolescent Psychiatry Department of Psychiatry and Behavioral Medicine Medical College of Wisconsin 8701 Watertown Plank Road, Milwaukee, WI 53295
07/2003-06/2007	Chucker Aring Chair, Child Psychiatry Children's Hospital of Wisconsin Medical College of Wisconsin

**10. Educational Administrative Appointments:**

06/2000-06/2003	Director, Child and Adolescent Psychiatry Training. UT Southwestern Medical Center, Dallas, TX
10/2008-06/2009	Interim Director, General Psychiatry Residency Kansas University School of Medicine - Wichita

**11. Hospital and Clinic Administrative Appointments:**

01/2013 – 05/2016	Kansas University Medical School, Wichita, Inpatient Attending, Child and Adolescent Psychiatry Unit at the Behavioral Health Center, Via Christi Hospital and Health Center. Wichita, KS.
2008 - 2014	Medical Director, Sequel Inc. Riverside and Lakeside Academy, Wichita, KS.
06/2007- 04/2013	Medical Director for Behavioral Health, Via Christi Hospitals and Health System, Wichita, KS
07/2003 – 06/2007	Medical Director, Children's Hospital of Wisconsin 9000 W. Wisconsin Avenue, Milwaukee, WI 53201
07/2003–06/2007	Medical Director/Consultant Child and Adolescent Psychiatry Rogers Memorial Hospital, West Allis, WI
06/2000-06/2003	Director, Pediatric Bipolar and Psychotic Disorders Clinic UT Southwestern Medical Center
07/1998-06/2000	Director, Child and Adolescent Psychiatry Clinic Eisenhower Army Medical Center, Fort Gordon, GA. 30905

01/2000-06/2000	Acting Chief, Inpatient Psychiatry Eisenhower Army Medical Center, Fort Gordon, GA. 30905
07/1996-06/1998	Director, Inpatient Psychiatry (The largest active duty ward in the Army) Darnall Army Community Hospital, Fort Hood, TX

Cigna Committees:

6/2017 - present	Salute ERG / Veteran CRG
2017 - present	IRR behavioral health Committee, Co-Chair
04/2019 – present	PMRS Specialty Review Committee
06/2019 – present	Clinical Performance & Quality Committee
06/2018 – present	ABLE ERG / Cigna Disabilities CRG
08/2017 – present	IRR behavioral health Committee, Co-Chair
04/2019 – present	PMRS Specialty Review Committee
06/2019 – present	Clinical Performance & Quality Committee
09/2019 – present	CBH Credentialing Committee, Chair
03/2021 – present	Co-Chair Community Relations Committee, UpNext ERG

**12. Hospital Staff Privileges:**

07/1995-06/1996	D.D. Eisenhower Army Medical Center, Bldg 300, Fort Gordon, GA. 30905
07/1996-06/1998	Darnall Army Community Hospital Fort Hood, TX.
07/1998-06/2000	D.D. Eisenhower Army Medical Center, Bldg 300, Fort Gordon, GA. 30905
06/2000-06/2003	Children’s Medical Center of Dallas Motor Street, Dallas, TX 75235
06/2000-06/2003	Parkland Memorial Hospital, 5201 Harry Hines Blvd, Dallas, TX 75235
06/2000-06/2003	Zale-Lipshy University Hospital, Harry Hines Blvd, Dallas, TX 75235
07/2003-06/2007	Children’s Hospital of Wisconsin 9000 W. Wisconsin Avenue, Milwaukee, WI 53201
07/2003-06/2007	Rogers Memorial Hospital, 111 <sup>th</sup> and Lincoln Avenue, West Allis, WI
06/2007-05/2016	Via Christi Hospitals and Health System Wichita, KS

Other Activities

1996-present	Expert witness, case reviews, and case value assistance.
2015-2016	mcmc: Independent contractor for Independent Medical Reviews.

**13. Specialty Boards and Certification:**

Board Certified:  
American Board of Psychiatry and Neurology:

General Psychiatry, April 1996.  
Part I - passed October 1995  
Part II - passed April 1996 - #42653  
Recertified July 2006-2016; 2016-2026

Child and Adolescent Psychiatry, September 1996 - #4262  
Recertified May 2006-2016; 2016-2026

Advanced Trauma Life Support, and Combat Casualty Care Course. Fort Sam Houston, Texas;  
10/1991.

State Medical Licenses:

Wisconsin	# 45790-020	2003-2007
Texas	# L0568	2000-2003 2016-present
North Dakota (LT)	# 8193	1999
Georgia	# 046485	1998-2001
South Carolina	# 20691	1998-2001
Kansas	# 04-24308	1992-2001 & 2007-present

NPI # 1144274028

**14. Awards and Honors:**

1981	State of Kansas Scholar
1982	Presidential Nomination and Appointment. United States Military Academy, (USMA) West Point, NY.
1982	Marvin Grimm Outstanding Student Athlete Award University of Nebraska. Lincoln, Nebraska.
1995	Al Glass: Resident Research Award and Lecture, Army Medical Department, Behavioral Science Postgraduate Short Course. Miami, FL.
1995	Joe and Hope Skobba Memorial Award and Lecture for Resident Research. Georgia Psychiatric Physicians Association Winter Meeting. Atlanta, GA.
1996	Army Medical Department (AMEDD) Behavioral Science Postgraduate Short Course, Resident research competition winner. San Diego, CA.
1996	Joe and Hope Skobba Memorial Award and Lecture for Resident Research. Georgia Psychiatric Physicians Association Winter Meeting. Atlanta, GA.
1996	APA/Lilly Resident Research Award. APA Annual Meeting. New York, NY.
1996	APA Research Colloquium for Young Investigators. Child Psychiatry Research Subgroup. New York, NY.
1996	Al Glass Military Psychiatry Resident Research Award. Society of

	Military Psychiatry Annual Meeting. New York, N.Y.
1996	Lilly Fellowship Award. Annual Meeting, Society of Biological Psychiatry. New York, NY.
1996	Pfizer Psychiatric Residents of the Year Award. Annual Meeting, American Psychiatric Association, New York, NY
1997	Nominated for Surgeon General's Physician Recognition Award, by the Consultant to the Surgeon General for Psychiatry
1999	Outstanding Teacher Award, Child and Adolescent Psychiatry D.D. Eisenhower AMC, Fort Gordon, GA
2002	Outstanding Teacher Award, Child Psychiatry Division UT Southwestern Medical Center
2002	Future Leaders in Psychiatry, Miami, Fl. April 2002
2003-2007	Chucker Aring Professor of Child Psychiatry Children's Hospital of Wisconsin/MCW
2005-2015	Best Doctors in America
2007	Anthony Meyer Best Teacher Award, Childs and Adolescent Psychiatry Division Medical College of Wisconsin
2007-2008	America's Top Psychiatrist
2010	KUMC Endowment Association Early Career Award October 2010

**15. Membership in Professional and Honorary Societies:**

1989-1997	Kansas Medical Society
1989-present.	American Medical Association
1990-present.	American Psychiatric Association
1994-present.	American Academy of Child and Adolescent Psychiatry
1997-1998	Texas Society of Psychiatric Physicians
1998-2000.	Georgia Psychiatric Physicians Association
2000-2010	International Early Psychosis Association
2000-2003	Texas Society of Child and Adolescent Psychiatry
2001-2016	International Society for Bipolar Disorders
2000-2003	Texas Society of Psychiatric Physicians
2003-2007	Wisconsin Psychiatric Association
2003-2007	Wisconsin Council of Child and Adolescent Psychiatry
2004-2006	Wisconsin Medical Society
2004-2007	Wisconsin Chapter of the American Academy of Pediatrics
2005-2014	International Society for Affective Disorders
2007-present	Kansas Medical Society
2007-2017	Medical Society of Sedgwick County
2007-present	Kansas Psychiatric Society
2007-2012	American Academy of Chairs of Departments of Psychiatry
2009-2012	International Society of Psychiatric Genetics
2017-2019	American Association of Physician Executives

**16. Editorial Boards / Peer Reviewer:**

1999-2011	Schizophrenia Research - Reviewer
-----------	-----------------------------------

2000-2012	Academic Psychiatry - Reviewer
2001-2010	Biological Psychiatry- Reviewer
2001-2011	Bipolar Disorders- Reviewer
2001-2017.	Journal of the American Academy of Child and Adolescent Psychiatry- Reviewer
2002-2008	Journal of Psychiatric Research - Reviewer
2003-2007	Neuroscience Letters- Reviewer - Reviewer
2004-2013	Journal of Affective Disorders- Reviewer
2004-2008	Current Psychiatry- Reviewer
2005-2016	Journal of Child and Adolescent Psychopharmacology-Reviewer
2005-2016	Journal of Pediatrics- Reviewer and Guest Editor
2005-2010	Journal of Clinical Psychiatry – Reviewer
2006-2007	Journal of Pediatric Hematology and Oncology-Reviewer
2006-2010	NeuroImage - reviewer
2008-2010	Journal of the American Academy of Child and Adolescent Psychiatry, (Editorial Board)
2008-2014	Archives of General Psychiatry
2008-2016	Annals of General Psychiatry – Reviewer
2009-2016	Schizophrenia Bulletin – Reviewer
2010-2016	Psychiatry Research Neuroimaging

**16. Regional/Local/Appointed Leadership and Committee Positions:**

2000-2003	Vice President, Client Services, Member of Board of Directors. Child and Family Guidance Center. Dallas, TX
2001–2003	Members in Training Committee Texas Society of Psychiatric Physicians
2001–2003	Executive Committee Texas Society of Psychiatric Physicians
2003–2004	Treasurer, Texas Society of Child and Adolescent Psychiatry
2003–2007	Chair, Psychiatry Specialty Group Children’s Specialty Group, MCW
2003-2007	Southeast Wisconsin Child and Adolescent Psychiatry group. (Founder)
2004-2006	Clinical Quality Forum for Medical Directors and Physician Presidents/CEOs Wisconsin Medical Society
2005-2007	Committee on Psychological Aspects of Child and Family Health.
01/2005-2007	Wisconsin Chapter of the American Academy of Pediatrics Executive Council Member
01/2005-2007	Wisconsin Chapter of the American Academy of Pediatrics Executive Leadership Group
01/2005-2007	Wisconsin Council of Child and Adolescent Psychiatry Program Committee Chair
10/2005-2007	Wisconsin Council of Child and Adolescent Psychiatry Advisory Board: Center for the Study of Developmental

	Psychopathology in Vulnerable Youth (DPVY). University of Wisconsin Medical Center.
2006-2007	President-Elect Wisconsin Chapter of the American Academy of Child and Adolescent Psychiatry
2006-2007	Child Psychiatry Representative to the Wisconsin Psychiatric Association Executive Committee
2007	Member, Mental Health Drug Advisory Board. Wisconsin Health and Human Services.
2008	Elected President Wisconsin Chapter of the American Academy of Child and Adolescent Psychiatry
2007-	Health Information Management Committee Via Christi Hospital, Wichita, KS
2007-2012	Computerized Physician Order Entry Committee Via Christi Hospital, Wichita, KS
2008-2014	Vice Chair, Psychiatry Section Via Christi Hospital, Wichita, KS
2008-2014	Medicine Section Member Via Christi Hospital, Wichita, KS
2009-2012	Kansas Health Policy Authority State of Kansas
	Mental Health Advisory Council
2009-2012	Kansas Health Policy Authority State of Kansas
	At-Large Advisory Council
2009	Medical Society of Sedgwick County Delegate to the Kansas Medical Society
2010	Search Committee member
	Associate Dean of the School of Pharmacy - Wichita campus
2011	Strategic Planning Committee for KUMC Innovation sub-committee

**18. National Elected/Appointed Leadership and Committee Positions:**

1997-1999	Outcomes Research Committee
	American Academy of Child and Adolescent Psychiatry
2002 – 2005	PANSS Master International Scoring Team Global Interrater Rater Reliability for Adolescents. Pharmanet / Janssen
2002-2006	Board Examiner: Child and Adolescent Psychiatry
2002-2004	Michael Smith Foundation for Health Research. I do peer reviews for research career development awards. Vancouver, BC
2003-2004	Board Examiner: General Psychiatry
2003-2005	Pediatric Bipolar Disorder Guidelines Committee Child and Adolescent Bipolar Foundation
2003	OPTIONS Treatment Guidelines and Education A national committee to form a consensus for treatment of Bipolar Disorder in adults and children. Sponsor: Medical Decision Point



2003–2004	National Institutes of Health Ad Hoc Reviewer CPDD Child Psychopathology and Developmental Disabilities.
2003-2011	National Institutes of Health Ad Hoc Reviewer Special emphasis panel BPPP, member.
2004-2012	National Institutes of Health Member Reviewer F12B, Psychopathology, Developmental Disabilities, Stress and Aging Fellowship Review Committee.
01/2006-2007	Protocol Design, Planning and Development Team Questionnaire/Psychosocial Measures Committee National Childhood Study Waukesha County Vanguard Center

**19. Research Grants, Contracts, Awards, Projects:**

**Peer Review:**

Title: The First Break Psychosis Study. D.D.Eisenhower AMC  
Source: NIMH/DoD  
Role: Co-Investigator, Local PI  
Dates: 1992 – 1998, 2000 to 2004  
Direct Funds: \$755,000

Title: National Collaborative Study of Early Psychosis and Suicide (NCSEPS): A  
collaboration between the Department of Defense (DoD), Veterans Administration  
Health System and the National Institute of Mental Health (NIMH) to decrease  
psychiatric morbidity and suicide among DoD personnel.  
Source: NIMH  
Role: DoD Consultant  
Dates: 1996-2002

Title: Pediatric Bipolar Collaborative Mood Stabilizer Trial  
Source: NIMH  
Role: Principal Investigator  
Dates: September 2000-August 2005  
Direct Funds: \$1,238,000

Title: Fluoxetine for the Treatment of Major Depression in Youth with Bipolar Disorder  
Source: NIMH, Research Units for Pediatric Psychopharmacology  
Role: Principal Investigator (Dallas site)  
Dates: 2000-2001  
Direct Funds: \$40,000

Title: Adjunctive Use of Stimulant Medication for ADHD Co-Morbid with Pediatric  
Bipolar Disorder.  
Source: Stanley Medical Research Foundation  
Role: Principal Investigator  
Dates: 2000-2003  
Direct Funds: \$100,000

Title: Omega 3 Fatty Acids and Antioxidant Treatment of Pediatric Bipolar Disorders and Psychotic Disorders.

Source: Stanley Medical Research Foundation

Role: Principal Investigator

Dates: 2001-2003

Direct Funds: \$90,000

Title: Pilot Study on the Safety and Effectiveness of Add-on Topiramate to Mood Stabilizing Treatment in Children and Adolescents with Bipolar Disorder.

Source: Stanley Medical Research Foundation

Role: Principal Investigator

Dates: 2001-2003

Direct Funds: \$150,000

Title: Collaborative Lithium Trial (COLT): This is a multisite study of lithium use in patients with pediatric onset Bipolar Disorder. The study includes establishing pharmacokinetics, safety, and dose finding.

Source: NICHD, RFA

Role: Principal Investigator

Dates: Funded 1 October 2005 (3 year application)

Direct Funds: 580,000 plus contract per patient

Title: NIH's National Children's Study: This study involving 1,250 children from birth to 21 years of age.

Source: NICHD, RFA

Role: Mental Health Consultant, Scientific Advisory Board Member, National Questionnaire/Psychosocial Measures Committee

Dates: Funded October 2005-2007

Title: Pharmacogenomic and Spectroscopy Predictors of Response to Lithium Treatment

Source: Healthier Wisconsin

Role: PI

Dates: 2005-2007

Direct Funds: \$40,000

Title: A zebrafish model for evaluating lithium treatment efficacy in lead-exposed children

Children's Environmental Health Institute Investigator: PI: Daniel N. Weber

Co-PI: Russel Scheffer, M.D. 2006-2007 Direct funds: \$70,000

Title: Behavioral Health Program in the Fox Valley: A Primary Care Collaboration for Child and Adolescent Psychiatry in the Fox Valley of Wisconsin

Source: Robert Wood Johnson Foundation Local Initiatives

Role: PI; consultant

Dates 2007-2010

Direct Funds: \$500,000

Title: Collaborative Lithium Trial (CoLT, Phase 2): This is a multisite study including a randomized controlled trial, maintenance phase, randomized discontinuation phase, and a restabilization phase.

Source: NICHD

Role: PI

Dates: 10/2009-2012

Direct Funds: \$550,000

Total Funds: \$812,350

Title: CoLT Pharmacogenetics Study

Stanley Medical Research Foundation

Role: Site PI

Dates: 2009-2012

### **Peer Reviewed But Not Funded:**

Title: Genetic Linkage of Early Age Mania (GLEAM): This is a multisite collaborative RO1 concerned with genetic linkage studies involving multiplex families with mania.

Source: NIMH RFA Score 201, 30%tile

Role: Principal Investigator

Dates: Submitted 1 March 2005 (5 year application)

Direct Funds: 1,300,000

Title: Wisconsin Pediatric Psychiatry Collaborative Care Program: This health services research proposal would provide statewide support for primary care clinicians in treating children and adolescents with common psychiatric disorders. 13%tile but not funded

Source: Healthier Wisconsin

Role: Principal Investigator

Dates: Submitted 4 April 2005 (3 year proposal)

Direct Funds: \$150,000

### **Non-Peer Reviewed:**

Title: Skin Fibroblast Studies in Childhood Psychosis and Children at Risk for Psychosis.

Role: Principal Investigator

Dates: 1993-1996.

Title: Dexamethasone Augmentation in the Treatment of Major Depression.

Sponsor: D.D.Eisenhower AMC

Role: Principal Investigator

Dates: 1992 - 1995.

Title: Application of Advanced Voice Recognition Technology in the Assessment of Depressive and Anxiety States- A Pilot Study. This study aims to determine if advanced voice recognition technology can differentiate between psychiatric patients and normal controls.

Role: Principle Investigator

Sponsor: D. D. Eisenhower Army Medical Center.

Dates: April 1999 to May 2000.

Title: A Double-Blind, Placebo-Controlled Exploratory Study of Sertraline in Adolescent Outpatients with Nondelusional Major Depressive Disorder.

Source: Pfizer

Role: Principal Investigator D.D. Eisenhower AMC;

Dates: 1994-1995.

Title: A Follow-up Study of First Episode Psychoses.

Sponsor: Department of Defense

Role: Principal Investigator

Dates: 1994 - 1998.

Title: Gulf War Syndrome, Post-Traumatic Stress Disorder Study in Gulf War Veterans.

Sponsor: Department of Defense

Role: Clinical Rater. 1994-1999.

Title: Lipid Peroxidation in Children and Adolescents with Attention Deficit Hyperactivity Disorder.

Role: Principal Investigator

Sponsor: Medical College of Georgia.

Dates: 1995-1996.

Title: Normal and Psychiatric Controls for The Neurological Evaluation Scale and The Premorbid Adjustment Scale.

Role: Principal Investigator

Sponsor: D.D. Eisenhower AMC

Dates: 1995.

Title: A Cross-Cultural Study of Schizophrenia: Diet, Fatty Acid Metabolism and Outcome in The United States and Rural India.

Role: Principal Investigator

Dates: 1995 - 2000.

Title: The Efficacy and Safety of Risperidone in the Treatment of Children and Adolescents with Schizophrenia

Source: Janssen

Role: Principal Investigator

Dates: 2001-2003

Direct Funds: \$13,000 per patient

Title: A Genetic Study of Mood Disorders in Children, Adolescents and Their First Degree Relatives

Source: UT Southwestern Foundation

Role: Co-Investigator

Dates: 2001-2003

Title: A Double-Blind Placebo-Controlled 4-Week Study of the Safety and Efficacy of Study Drug In Children And Adolescents with Acute Manic or Mixed Episodes of Bipolar I Disorder, With An Optional 6-Month Open-Label Extension

Source: Ingenix: PDMD-009

Role: Principal Investigator

Dates: 2002-2003

Direct Funds: \$12,000 per patient

Title: An Open Label Trial of Adjunctive Zonisamide for Pediatric Bipolar I or II Disorder. (Role: PI, Investigator initiated).

Title: Ethyl-EPA Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder. Principle Investigator.

Sponsor: Laxdale Ltd

Role: Principal Investigator

Direct costs \$40,000.

Title: Ethyl-EPA Treatment of Children and Adolescents with Bipolar Affective Disorder and Psychotic Disorders. Sponsor: Laxdale Ltd: Role: Principle Investigator. Direct costs \$40,000.

Title: FID-MC-HGIU: Study drug versus Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder.

Source: Eli Lilly

Role: Principal Investigator

Dates: 2002-2003.

Direct Funds: \$13,000 per patient

Title: A Pilot Study of Safety and Effectiveness for Depakote ER in Pediatric Bipolar Disorder

Source: Abbott Labs

Role: Principal Investigator-Investigator initiated

Dates: 2002-Dec 2005

Direct Funds: \$50,000

Title: Ziprasidone Treatment of Early Onset Psychotic Disorders.

Source: Pfizer

Role: Principal Investigator- Investigator initiated

Dates: 2002-2006

Direct Funds: \$60,000

Title: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg and 800 mg Compared with Placebo in the Treatment of Adolescents with Schizophrenia

Source: AstraZeneca

Role Principal Investigator

Dates: August 2004 – 2007

Direct Funds: \$13,650.00 per completed patient

Title: A 3-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) Immediate-release Tablets in Daily Doses of 400 mg and 600 mg Compared with Placebo in the Treatment of Children and Adolescents with Bipolar I Mania

Source: AstraZeneca

Role Principal Investigator

Dates: August 2004 – 2007

Direct Funds:\$11,750.00 per completed patient

Title: A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents with Bipolar I Disorder and Adolescents with Schizophrenia

Source: AstraZeneca

Role Principal Investigator

Dates: August 2004 – 2007

Direct Funds: \$13,725.00 per completed patient

Title: A Multi-Center, Open-Label Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2 mg-30 mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features

Source: Otsuka Maryland Research Institute, Inc.

Role Principal Investigator

Dates: November 2004 – July 2006

Direct Funds: \$8,845.00 per completed patient

Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Oral Doses of Aripiprazole (10 mg or 30 mg) in the Treatment of Child and Adolescent Patients, Ages 10-17, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features

Source: Otsuka Maryland Research Institute, Inc.

Role Principal Investigator

Dates: November 2004 – July 2006

Direct Funds: \$19,685.00 per completed patient

Title: A 3-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) Immediate-release Tablets in Daily Doses of 400 mg and 600 mg Compared with Placebo in the Treatment of Children and Adolescents with Bipolar I Mania Study

Code:D1441C00149

Sponsor: Astrazeneca

Role: Principal Investigator

Direct Cost: \$11,750 per completed patient

Dates: November 2004 - July 2006

Enrollment goals: 12 Participants

Fixed Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Two Oral Doses of Aripiprazole in the Treatments of Child and Adolescent Patients, Ages 10-17 Years, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features  
Source: Otsuka 031-03-240.  
Role: Principal Investigator  
Dates: January 2005-2007  
Direct Funds: \$23,622 per completed patient

Title: A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents with Bipolar I Disorder and Adolescents with Schizophrenia  
Source: Astrazeneca  
Role: Principal Investigator  
Dates: November 2004- 2007  
Direct Funds: \$13,725 per completed patient through January 2009 Enrollment goals: 12 participants

Title: A 3-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) Immediate-release Tablets in Daily Doses of 400 mg and 600 mg Compared with Placebo in the Treatment of Children and Adolescents with Bipolar I Mania Study  
Code: D1441C00149  
Source: Astrazeneca  
Role: Principal Investigator  
Dates: November 2004-July 2006  
Direct Funds: \$11,750 per completed patient

Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Adolescent Patients with Schizophrenia.  
Source: Otsuka Maryland Research Institute, Inc.  
Role: Principal Investigator  
Dates: April 2005 – July 2006  
Direct Funds: 9,166.67 per completed patient

Title: 4-Week, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating The Efficacy, Safety and Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescent Subjects With Bipolar I Disorder (Manic Or Mixed)  
Source: Pfizer  
Role: Principal Investigator  
Dates: December 2005 – 2007  
Direct Funds: \$6,050.00 per completed patient

Title: 26-Week, Open-Label, Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I

Disorder (Manic Or Mixed)  
Source: Pfizer  
Role Principal Investigator  
Dates: December 2005 – 2007  
Direct Funds: \$5,756.25 per completed patient

Title: Six Week, Double-Blind, Placebo-Controlled Phase III Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Flexible Doses of Oral Ziprasidone in Adolescent Subjects with Schizophrenia  
Source: Pfizer  
Role Principal Investigator  
Dates: December 2005 – 2007  
Direct Funds: \$8,556.25 per completed patient

Title: 26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Adolescent Subjects with Schizophrenia  
Source: Pfizer  
Role Principal Investigator  
Dates: December 2005 – 2007  
Direct Funds: \$6,550.00 per completed patient

Title: A Double-Blind Flexible Dose Study of Escitalopram in Pediatric Patients with Major Depressive Disorder  
Source: Forest Research Institute  
Role Principal Investigator  
Dates: April 2006 – 2007  
Direct Funds: \$8,270.90 per completed patient

Title: A Double-Blind, Fixed-Dose Extension Study of Escitalopram in Pediatric Patients With Major Depressive Disorder  
Source: Forest Research Institute  
Role Principal Investigator  
Dates: April 2006 – 2007  
Direct Funds: \$6,742.50 per completed patient

A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 years with Acute Manic or Mixed Bipolar I Disorder.  
Source: Shire  
Role Principal Investigator  
Dates: August 2006 – August 2007  
Direct Funds: \$6,230 per completed patient

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study with Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents with Autistic Disorder.  
Source: Bristol-Myers Squibb



Role Principal Investigator  
Dates: July 2006 – 2007  
Direct Funds:\$7,541 per completed patient

A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder.

Source: Bristol-Myers Squibb  
Role Principal Investigator  
Dates: July 2006 – 2007  
Direct Funds:\$8,656 per completed patient

Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Adolescent Patients with Schizophrenia. Protocol No. 31-03-239

Source: Otsuka Maryland  
Role: Principal Investigator  
Dates: November 2005 – December 2006  
Direct Funds: \$11,458.34 per completed patient (4)

Title: A Multi-Center, Open-Label, Safety Study of Flexible-Dose Oral Aripiprazole (2mg – 30mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode Protocol 31-03-241

Source: Otsuka Maryland  
Role: Principal Investigator  
Dates: November 2004- 2007  
Direct Funds: \$8,845.00 per completed patient

Title: An 8 Week, Multicenter, Open-Label, Flexible-Dose Study to Evaluate the Safety, Efficacy, and Tolerability of Desvenlafaxine Succinate Sustained-Release Tablets in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder.

Protocol: 3151A6-2000-US  
Role: PI  
Sponsor: Wyeth Research  
Dates: March 2008 – March 2013

Title: A 6 Month, Multicenter, Open-Label, Flexible-Dose Study to Evaluate the Safety, Efficacy, and Tolerability of Desvenlafaxine Succinate Sustained-Release Tablets in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder.

Protocol: 3151A6-2000-US  
Role: PI  
Sponsor: Wyeth Research  
Dates: March 2008 – March 2013

Additional ongoing studies (Acute and follow up)

Bipolar Disorder

Wyeth/Pfizer  
Otsuka

Schizophrenia  
Wyeth/Pfizer  
Otsuka

Autism  
Forest

Other studies:

Clinical evaluator, for psychopharmacology trials involving risperidone, clozapine and olanzepine. Augusta GA, Department of Veterans Affairs hospital. 1991-1993.

Neuroendocrine research assistant at Kansas University, Lawrence, Kansas. Dr. David Quadagnos' lab; 1986 - 1987. performed a variety of duties including small animal surgeries, stereotactic brain implants and behavioral observations.

Affiliated Investigator, Center for the Study of Cultural Diversity in Healthcare  
University of Wisconsin, Madison 2005 to 2007

Data Safety and Management Boards:

2002-2005      Quetiapine in Bipolar Disorder and Co-morbid Substance Abuse: UT  
Southwestern Medical Center. PI: Sherwood Brown, M.D., Ph.D.

02002-2004      Asperger's Disorder as a Negative Symptom Spectrum Disorder: An Open Trial  
of Risperidone. Medical College of Georgia. PI: Jeffrey L. Rausch, M.D., Donna  
Londino, M.D.

**20. Invited Lectures/Workshops/Presentations/Site Visits:**

**International:**

Scheffer RE, Cell Membrane Pathology at the Onset of Psychosis. Invited participant 1st and 2nd International Workshop on Cell Membrane Pathology in Schizophrenia. Augusta, GA. March 1993, and London, UK. October 1995.

Scheffer RE: Preschool Mania, Does it really exist? In :Bipolar Symposium with Gabriele Masi, Steven Dilsaver, Kostas Fountoulakis, and Heinz Grunze, Akiskal H. and Kaprinis CoChairs. Lisbon, Portugal, March 2006

Scheffer RE: The management of ADHD Bipolar comorbidity in children. In: Athens, Greece, Dec 2006

EEG test-result subgroups of ADHD patients showed significant and clinically meaningful differences S.M. Snyder, Ph.D.1, T.A. Rugino, M.D.2, W.B. Daviss, M.D.3, M. Hornig, M.D.4, **R.E. Scheffer, M.D.5**, R. Davis, M.D.6, N.M. Handal, M.D.7, G. Hopkins, M.D.8, P.E. Knott, M.D.9, H.R. Lessin, M.D.10, T.M. Lock, M.D.11, G.

Marsella, M.D.<sup>12</sup>, R. McBurnett, Ph.D.<sup>13</sup>, J.J. Nandagopal, M.D.<sup>14</sup>, D. Peeples, M.D.<sup>15</sup>, R. Ranjan, M.D.<sup>16</sup>, E.H. Sarkis, M.D.<sup>17</sup>, G.E. Tsai, M.D., Ph.D.<sup>18</sup>, A.S. Unis, M.D.<sup>19</sup>, R.A. Williams, Ph.D.<sup>20</sup> EEG test-result subgroups of ADHD patients showed significant and clinically meaningful differences. Canadian ADHD

**National:**

Kowatch RA, Scheffer RE: a double-blinded, controlled trial of valproate, risperidone and placebo in children ages 3-7 yr. with Bipolar Disorder. Submitted to AACAP Annual Meeting Oct 2011.

Scheffer RE: Depression and Anxiety: Medication Effectiveness and Assessing the Suicide Risk. Editors Choice CME Meeting. Milwaukee, WI. June 2005.

Dr. Scheffer has made more than 50 paper presentations at scientific meetings and Grand Rounds (Psychiatry, Pediatrics, Obstetrics/Gynecology, Family Medicine) in addition to those above. Recent topics include:

Differentiating ADHD from Pediatric Bipolar Disorder  
Rational Selection of Atypical Antipsychotics in Children and Adolescents  
Conducting Clinical Trials in Severely Ill Children  
Neurodevelopment and Schizophrenia  
Cell Membrane Pathology and Fatty Acid Metabolism  
Pediatric Bipolar Disorder, Diagnosis, Epidemiology, Phenomenology, and Treatment  
Pediatric Psychotic Disorders  
The Use of Antipsychotics in Children and Adolescents  
ADHD: Diagnosis and Treatment  
ADHD: Co-morbidities and Treatment  
Proposed approaches for early intervention in Schizophrenia and Bipolar Disorder  
Psychiatric Collaborative Care in Primary Care Settings

**Regional:**

Scheffer RE: What's in the Drug Development Pipeline? New Agents for the Child Psychiatrist. Annual Meeting of the Wisconsin Psychiatric Association. April 2005.

Scheffer RE: Unmet Needs in Pediatric Bipolar Disorder. Wisconsin Psychiatric Association Annual Meeting. Milwaukee, WI. November 2003.

**Local:**

Scheffer RE: Psychopharmacology of Affective Disorders in Children and Adolescents. J. Frazier Snyder Conference. Children's Hospital of Wisconsin. November 2003.

Scheffer RE: Juvenile Bipolar Disorder: Diagnostic Strategies for the Clinician. J. Frazier Snyder Conference. Children's Hospital of Wisconsin. November 2003.

21. **Peer Reviewed Workshops/Presentations:**

**International:**

Snyder, S.M., Rugino, T.A., Hornig, M., Daviss, W.B., Scheffer, R.E., Williams, R.A., Tsai, G.E., Davis, R., and K. McBurnett. EEG as a Biomarker Separated ADHD Patients into Clinically Meaningful Subgroups. *European Society of Child and Adolescent Psychiatry*. Helsinki, Finland. June 2011.

Snyder, S.M., Rugino, T.A., Hornig, M., Daviss, W.B., Tsai, G.E., Lock, T.M., Marsella, G., Davis, R., Scheffer, R.E., Williams, R.A., and K. McBurnett. An Electroencephalographic Biomarker Separated Patients with Attention-Deficit/Hyperactivity Disorder into Two Subgroups with Significantly Different Clinical Profiles. *International Congress on ADHD*. Berlin, Germany. May 2011.

Scheffer, RE, Apps, JN: A Pilot Study of the Safety and Effectiveness of Divalproex ER in Pediatric Bipolar Disorder. Annual Meeting: American Psychiatric Association. Toronto, Ont. May 2006

Scheffer, RE, Apps JN: Preschool mania: Does it exist? Biennial meeting International Society of Affective Disorders. Lisbon, Portugal March 2006.

Scheffer RE, Niskala JA, Haroon S: Diagnosis and Treatment of Mania in Preschool Children. NIMH Pediatric Bipolar Disorder Conference. March 2003.

**National:**

Adelaide Robb, M.D., Robert Findling, M.D., MBA, Russell Scheffer, M.D., Vivian Kafantaris M.D., Robert Kowatch MD, PhD. Collaborative Lithium Trial. Annual Meeting of the AACAP. San Diego, CA October 2014.

Robert A. Kowatch, MD, PhD, Scheffer RE: Placebo Controlled Trial of Valproate Versus Risperidone in Preschool Children with Bipolar Disorder. Academy of Child and Adolescent Psychiatry San Francisco, CA Oct 2012.

Robert A. Kowatch, MD, PhD, Robert L. Findling, MD, Russell E. Scheffer, MD. Pediatric Bipolar Collaborative Mood Stabilizer Trial. Annual Meeting, American Academy of Child and Adolescent Psychiatry. Chicago, IL Oct 2008

Robert A. Kowatch, MD, PhD, Robert L. Findling, MD, Russell E. Scheffer, MD, PhD & Kevin Stanford, MPH Pediatric Bipolar Collaborative Mood Stabilizer Trial Annual Meeting, American Academy of Child and Adolescent Psychiatry. Boston, MA Oct 2007

E.A. Youngstrom, Ph.D., M.F. Joseph, B.A.; R.L. Findling, M.D.; J. Soares, M.D.; G.A. Carlson, M.D.; V. Kafantaris, M.D.; J. Wozniak, M.D.; K. Chang, M.D.; J.A. Frazier, M.D.; M.A. Fristad, Ph.D.; M.P. DelBello, M.D., M.S.; R.A. Kowatch, M.D., Ph.D.; R. Scheffer, M.D.; E. Leibenluft, M.D. Young Mania Rating Scale Scores Across Twelve Research Groups. Annual Meeting, American Academy of Child and Adolescent

Psychiatry. Boston, MA Oct 2007

Scheffer, RE, Apps, JN: Conversion of Divalproex DR to Divalproex ER in Pediatric Bipolar Disorder. Annual Meeting: American Psychiatric Association. San Diego, CA Oct. 2006

Kowatch RA, Findling R, Scheffer, RE: Pharmacologic Treatment of Mania in Children and Adolescents, NCDEU Boca Raton, FL June 2006

Birmaher B, Kowatch RA, Fristad M, Luby J, Pavuluri M, Scheffer RE: Preschool mania, does it exist? Symposia Annual meeting American Academy of Child and Adolescent Psychiatry. Toronto, CA. October 2005.

Scheffer RE: Omega 3 Fatty Acids in the Treatment of Bipolar Disorder. Basic Science to Bedside. Child and Adolescent Bipolar Foundation Symposia. American Academy of Child and Adolescent Psychiatry Annual Meeting. October 2004.

Robb A, Scheffer RE, Denisco M: Clinical Trials: Current Issues and Future Directions. (Workshop). AACAP Annual Meeting. Miami, FL. October 2003.

Niskala JA, Scheffer RE, Aguilar IG: Bipolar Disorder in Preschool Children: Characterization, Treatment and Implications. American Psychological Association Annual Meeting. Toronto, Ont. August 2003.

Scheffer RE, Kowatch RA: Combination Pharmacotherapy In Pediatric Bipolar Disorders. (Symposia) Annual Meeting of the American Academy of Child and Adolescent Psychiatry. San Fransisco, CA. October 2002.

Scheffer RE, Kowatch RA, Hume J, Rush AJ: Psychostimulants Use in Pediatric Bipolar Disorder and Co-morbid ADHD. Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Honolulu, HI. October 2001.

22. **Kansas University School of Medicine - Wichita**

2007-2012	Executive Committee
2007-2012	Executive Faculty Committee
2008-2012	Faculty Development, Grand Rounds Committee
2008-2011	Promotions and Tenure Committee (All school)
2008-2012	WCGME Research Committee
2009-2010	Chair, Search Committee for the Associate Dean for Research and Chair of the WCGME research council
2009-2011	Dean's Excellence in Leadership committee

**Medical Practice Association, KU SOM-Wichita**

2007-2012	Executive Committee
2007-2012	Board of Trustees
2007-2012	Compliance Committee

2008-2012 Secretary Treasurer

**Clinical Research Institute**

2007-2012 Principal Investigator  
2009-2011 Chair, Board of Directors  
2009-2012 Chief Executive Officer

**Kansas Neuroscience LLC**

2010-2012 Chief Executive Officer  
2010-2012 Principal Investigator

**Kansas University Clinical Trials Unit**

2012-2014 Principal Investigator

**Medical College of Wisconsin/Children's Hospital of Wisconsin Committees:**

2003-2007 Executive Leadership Group  
Department of Psychiatry and Behavioral  
Medicine  
2003-2007 Clinical Services Group  
Department of Psychiatry and Behavioral  
Medicine  
2003-2007 Child Psychiatry Training Committee  
Department of Psychiatry and Behavioral  
Medicine  
2003-2007 Medical Leadership Committee  
Children's Hospital of Wisconsin  
2003-2007 Executive Leadership Committee  
Children's Hospital of Wisconsin  
Child and Adolescent Psychiatry Center  
2003-2007 Forms Committee- Psychiatry  
Children's Hospital of Wisconsin  
Child and Adolescent Psychiatry Center  
2003-2007 Education Committee  
Children's Hospital of Wisconsin  
Child and Adolescent Psychiatry Center  
2003-2007 Clinical Workgroup  
Children's Hospital of Wisconsin  
Child and Adolescent Psychiatry Center  
2004 Clinical Organization Workgroup  
Department of Psychiatry and Behavioral  
Medicine  
2004 Clinical Trials Workgroup, Co-Chair  
Department of Psychiatry and Behavioral  
Medicine  
2005-2007 Department of Psychiatry,  
Appointment, Promotion & Tenure committee

2005-2006	Department of Psychiatry Drug Industry Interaction Committee
2005-2006	Department Compensation Committee
2006-2007	Physician Health Committee Children's Hospital of Wisconsin

**University of Texas Southwestern Medical School Committees:**

2000-2003	Child and Adolescent Training Committee (Chair) Department of Psychiatry
2000-2003	Education Committee Department of Psychiatry
2001	Department Retreat Committee Department of Psychiatry
2000-2002	Service Committee Department of Psychiatry
2002-2003	Member, Institutional Review Board. UT Southwestern Medical Center

**D.D. Eisenhower Army Medical Center, Augusta, Georgia Committees:**

1991-1996	Journal Club Coordinator
1991-1996	Resident/Fellow Representative, Psychiatry Research Committee
07/1998-06/2000	Director of Psychiatric Research
1998-2000	Institutional Review Board
1998-2000	Pharmaceuticals and Therapeutic Committee (Assistant Chair)
1998-2000	Performance Improvement Coordinator
1998-2000	Continuing Medical Education Coordinator for Psychiatry
1998-2000	JCAHO Preparation Coordinator

**Darnall Army Community Hospital Fort Hood, Texas Committees:**

1996-1998	Pharmaceuticals and Therapeutic Committee
1996-1998	Drug Utilization and Evaluation Committee
1996-1998	Graduate Medical Education Committee

**Kansas University School of Medicine – Wichita**

**Medical Student Education**

2007-2013	Child and Adolescent Psychiatry Lecture Series
-----------	--

**Resident Education**

2007-2014	Child and Adolescent Psychiatry Rotation Camelot/Sequel Site Supervisor Child and Adolescent Psychiatry Clinic Site Supervisor Child and Adolescent Psychiatry Lecture Series
-----------	---

2008-2009	course leader Curriculum Review Committee Child and Adolescent Psychiatry
Oct 2008 – 2009	Director of Training, General Psychiatry Residency
2009	Curriculum Review Committee Research and Evidence Based Medicine
2012-present	Supervisor Inpatient Child and Adolescent Psychiatry

**Lay Public**

2008-2010	Health Education and Leadership Grant, 10 lecture series on psychiatric issues affecting physical health. Sponsor: Robert Woods Johnson Foundation
-----------	---

**Students, Faculty, Residents or Fellows Mentored:**

2007-present	Kristen Jones, ARNP, Psychopharmacology and phenomenology
2007-present	Kurt Leis, ARNP, Psychopharmacology and phenomenology

**23. Medical College of Wisconsin Teaching Activities:**

**Medical Student Education:**

07/2003-2007	I taught and supervised medical students rotating in Child Psychiatry. I meet individually with several students per year who are interested in Psychiatry as a career.
--------------	--

**Resident and Fellow Education:**

07/2003-2007	I supervised and mentored 1-3 fellows at all times. I was the primary supervisor at the pediatric psychopharmacology clinic. I meet with the fellows weekly with regards to staff development and administrative issues.
07/2003-2007	PGY2 Child Psychopathology, Course Director
07/2003-2007	Psychopharmacology, Co-Course Director
07/2003-2007	Bipolar disorder
07/2003-2007	ADHD
07/2003-2007	Psychotic disorders
07/2003-2007	Depressive Disorders
07/2004-2007	Neuroscience, Course Director
07/2004-2007	Research methods, Course Director

**Faculty Development/Continuing Medical Education:**

07/2003-2007	I initiated a weekly faculty development seminar focusing on clinical programs, research and
--------------	---



07/2003-2007	education. Psychopharmacology for Non-psychiatrists. A 4 hour CME course run at least annually.
2004	The NIH review process. Department of Psychiatry Faculty Development
2004-2005	Identification and Treatment of Pediatric Bipolar Disorder. I have been a featured speaker for this National CME program.
2005	Treatment of Aggression in Children and Adolescents. I have been a featured speaker for this National CME program.

**Community/Lay Public:**

07/2003-present	Annual presentations to National Alliance for the Mentally Ill (NAMI)
07/2003-present	Annual presentations to Depression and Bipolar Support Alliance
07/2003-present	Numerous appearances in local and national media regarding mental illnesses in youth.
2004-present	I work with state and national legislators regarding health care policy for psychiatrically ill youth.
2006-2007	Advisory Group member for the MHA primary care initiative

Note: I always (90+%) receive ratings of excellent or very good with regards to my teaching and lectures to all levels and specialties of professionals.

**University of Texas Southwestern Medical School Teaching Activities:**

**Medical Student Education:**

2000-2003	I taught and supervised medical students rotating in Child Psychiatry. I met individually with several students per year who were interested in Psychiatry as a career.
-----------	---

**Resident and Fellow Education:**

2000 to 2003	As training director, I completely revised the rotations and didactic teaching. I assisted in securing stable funding for the fellowship with enough additional income to offset many costs. I also secured permission and funding to expand the program from 4 to 5 residents per year. I received full accreditation for 5 years during the RRC review I was responsible for.
2000	Bipolar disorder
2001	Psychotic disorders
2002	Development, Course Director
2003	Psychopharmacology, Course Director

2004	Neuroscience, Course Director
2002-2003	Diagnostic interviewing, Course Director

**Faculty Development/Continuing Medical Education:**

2001	National CME program on Pediatric Bipolar Disorder (REACH)
------	--

**Community/Lay Public:**

2000-2003	Annual presentations to National Alliance for the Mentally Ill (NAMI)
2000-2003	Annual presentations to the Depressive, Manic-Depressive Association

**Medical College of Georgia/D.D. Eisenhower AMC Teaching Activities:**

**Medical Student Education:**

1991-1996	I taught and supervised medical students from the Medical College of Georgia and from Medical Schools throughout the country who rotated through the various areas in which I worked.
1998-2000	
1998 to 2000	Psychopharmacology: An overview of antipsychotics, antidepressants, anxiolytics and antimanic agents. (Junior Medical Students)

**Resident and Fellow Education:**

1998 -2000	Growth and Development
1998-2000	Psychopharmacology I
1998-2000	Psychopharmacology II
1998-1999	Military Psychiatry
1998-1999	History of Psychiatry
1998-1999	Psychodynamic Development

**24. Students, Faculty, Residents or Fellows Mentored:**

2000-2002	Scott Woods, M.D. Fellow/Faculty: Psychopharmacology and Phenomenology. Assistant Professor, UT Southwestern Faculty member.
2000-2002	Harlan Charleston, M.D. Fellow: Psychopharmacology and Phenomenology
2001-2003	Rupinder Bhatia, M.D. Fellow: Psychopharmacology Research. Conducts clinical research in Dallas, TX.
2002-2007	Jennifer Niskala Apps, Ph.D. Faculty: Patient centered research. Assistant Professor, Medical College of Wisconsin.
2003-2004	Paulina Kitcher, M.D. Fellow: Psychopharmacology and Phenomenology
2004-2005	Jessica Hoberg, R.N., CNP: Psychopharmacology and Phenomenology

2004-2006	Carolyn Turcott, M.D. Fellow: Psychopharmacology and Phenomenology
2005-2007	Jennifer Winkler, R.N. CNP: Psychopharmacology and phenomenology
2006-2007	Catherine Anderson, R.N., CNP: Psychopharmacology and phenomenology.

**25. Community Service Activities:**

2004-2007	Milwaukee Mental Health Association
2004-2007	Milwaukee Public Schools
2004-2007	Children’s Social Services of Wisconsin
2004-2007	Milwaukee Depression and Bipolar Support Alliance

**26. Programatic Developments:**

Fox Valley Mental Health	I proposed and received funding for a large program that supports primary care in the Fox Valley. This includes our coordination center, phone support, and Evaluation Clinic component and telepsychiatry support.
Bipolar Disorders Clinic	I developed and implemented the Pediatric Bipolar Disorder Clinic. This clinic has received national recognition. We evaluate patients from throughout the region and nation.
Research Clinic	The research clinic is closely integrated with the outpatient clinic and local inpatient services to provide as seamless a transition for patients as possible. The emphasis of the research is patient focused. We study psychopharmacological agents that have never been formally tested in youth. We also are actively examining neuroimaging, pharmacogenomics, and neuropsychological measures to help improve the effectiveness of treatments for youth. The goal is to decrease adverse events and morbidity by selecting agents that are more likely to be effective and less likely to cause side-effects.
Psychotic Disorders Clinic	I developed and implemented the Psychotic Disorders Clinic at CHW. We are a regional referral center for treatment and clinical research in youth with psychotic disorders.
Evaluation Clinic	We run a diagnostic evaluation clinic for primary care clinicians. The clinic provides thorough diagnostic evaluations and treatment guidelines for patients with ADHD, Depression and Anxiety Disorders.
Second Opinion Clinic	The clinic provides diagnostic clarification and psychopharmacology recommendations for a wide variety of conditions.
Child Psychiatry Clinic	I have overseen the complete revision of services at CHW with a 50% increase in patients seen in the clinic.
ADHD Clinic	We are developing comprehensive evaluation and

Depression	treatment options for youth with ADHD. A strong emphasis is placed upon psychoeducation. We are developing comprehensive evaluation and treatment options for youth with depression. A strong emphasis is placed upon psychoeducation.
Bipolar Psychosocial Clinics.	Cutting edge psychosocial treatments are being piloted and studied for this serious mental illness.

**27. Continuing Medical Education:**

2004-2007	Psychopharmacology for Non-Psychiatrists. Milwaukee, WI
2004-2005	Identification and Treatment of Pediatric Bipolar Disorder Series
2005	Disorders of Behavior and Aggression in Children and Adolescents Series

**28. Miscellaneous:**

1980	United States Olympic Trials Qualifier in Swimming
1981-1982	Varsity Swimming University of Nebraska at Lincoln
1983-1985	Varsity Swimming, USMA: West Point
1983-1985	Company G-1 Drug and Alcohol Counselor USMA: West Point
2005	Leadership Development for Physicians in Academic Health Centers Course. Harvard School of Public Health
2008	AAMC Development Course for Chairs and Associate Deans. Ft. Lauderdale, FL

**BIBLIOGRAPHY**

**Refereed Journal Publications/Original Papers**

1. Mahadik SP, Mukherjee S, Correnti EE, Kelkar H, Wakade CG, Costa RM, **Scheffer RE**: Distributions of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naive psychotic patients at the onset of psychosis. Schizophrenia Research. 1994; 13:239-247.
2. Mukherjee S, Mahadik S, Correnti EE, **Scheffer RE**, Kelkar H: Impaired antioxidant defense at the onset of psychosis. Schizophrenia Research. 1996; 19:19-26.
3. Mahadik S, **Scheffer RE**: Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 1996; 1.2:45-54.
4. Mahadik S, Shendarkar NS, **Scheffer RE**, Mukherjee S, Correnti EE: Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 1996; 1.2:65-70.

5. Mukherjee S, Mahadik S, Horrobin DF, Jenkins K, Correnti EE, **Scheffer RE**: Membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal controls. Psychiatry Research. 1996; 63(2-3):133-42.
6. Mahadik SP, Mukherjee S, **Scheffer RE**, Correnti EE, Mahadik JS: Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biological Psychiatry. 1998; 43:674-679.
7. Khan MK, Evans DR, Gunna V, **Scheffer RE**, Parikh VV, Mahadik SP: Reduced erythrocyte membrane fatty acids and increased lipid peroxides in schizophrenia at the never medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research. 2002; 58:1-10.
8. **Scheffer RE**: Pediatric Bipolar Disorder: Differential diagnosis and familial aspects of the illness. Paradigm. 2002; 6 (1) 12-13,22.
9. **Scheffer RE**: Abnormal Neurological Signs at the Onset of Psychosis. Schizophrenia Research (2004) 70 (1) 19-26, Sep 1.
10. **Scheffer RE**, Niskala JA: The Diagnosis and Treatment of Preschool Mania. J. Affect. Dis. (2004) 82: S25-S34.
11. **Scheffer RE**, Kowatch RA, Carmody T, Rush AJ: A Randomized Placebo-Controlled Trial of Adderall for Symptoms of Comorbid ADHD in Pediatric Bipolar Disorder Following Mood Stabilization with Divalproex Sodium. Am. J. Psych. (2005) 162 (1) 58-64.
12. Kowatch RA, Fristad, M, Birmaher, B, Wagner, KD, Findling, RL, Hellander, M: *Child Psychiatric Workgroup Members*. Treatment Guidelines for Children and Adolescents with Bipolar Disorder: Child Psychiatric Workgroup on Bipolar Disorders. J. Am. Acad. Child. Adol. Psych. (2005) 44 (3) 213-235.
13. **Scheffer RE**, Apps JN: ADHD or Bipolar Disorder? Core symptoms are key: Some behaviors are more helpful than others for making the correct diagnosis. Current Psychiatry (2005) 4(5) 42-52
14. **Scheffer RE**: Psychopharmacology: Clinical Implications of Brain Chemistry. Pediatric Clinics of North America (2006) 52(4): 767-776.
15. **Scheffer RE**: Childhood Onset Bipolar Disorder: A Role for Early Recognition and Treatment. J. Pediatrics 2007
16. **Scheffer RE**, Linden S: Concurrent Medical Conditions with Pediatric Bipolar Disorder. Current Opinion in Psychiatry (2007) 20:389-401.
17. **Scheffer RE**: Concurrent ADHD and Bipolar Disorder. Current Psychiatry Reports (2007) Vol 9 (5):415-419.

18. **Scheffer RE**: Concurrent ADHD and bipolar disorder: A 2009 perspective *Current Attention Disorders Reports*, (2009) 1:(3) 101-107.
19. **Scheffer RE**, Tripathi A, Kirkpatrick FG, Schultz T. Rapid Quetiapine Loading in Youths with Bipolar Disorder. *Journal of Child and Adolescent Psychopharmacology*. October 2010, 20(5): 441-445.
20. **Scheffer RE**, Tripathi A, Kirkpatrick FG, Schultz T: Guidelines for Treatment-Resistant Mania in Children with Bipolar Disorder. (2011) *Journal of Psychiatric Practice* Vol. 17, No. 3 p 186-193.
21. Kowatch RA, **Scheffer RE**: Risperidone and valproate treatment of preschoolers with mania. *Journal of Child and Adolescent Psychopharmacology*.
22. Findling RL, McNamara NK, Pavuluri MN, Frazier JA, Rynn M, **Scheffer RE**, Kafantaris V, Robb A, DelBello M, Kowatch RA, Rowles BM, Lingler J, Zhao J, Clemons T, Martz K, Anand R, Taylor-Zapata P. Lithium for the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled discontinuation study. *J Am Acad Child Adolesc Psychiatry* In press.

### **Books, Chapters and Reviews**

1. **Scheffer, RE**: *Psychiatric Disorders: Section IV: 2013*  
 Chapter 16: Somatoform Disorders  
 Chapter 17: Anxiety Disorders  
 Chapter 18: Depression and Bipolar Disorder  
 Chapter 19: Obsessive-Compulsive Disorder  
 Chapter 20: Pervasive Developmental Disorders and Psychoses  
*Nelson Essentials of Pediatrics* Elsevier, Philadelphia, PA, pending
2. **Scheffer, RE**: *Psychiatric Disorders: Section IV:*  
 Chapter 16: Somatoform Disorders  
 Chapter 17: Anxiety Disorders  
 Chapter 18: Depression and Bipolar Disorder  
 Chapter 19: Obsessive-Compulsive Disorder  
 Chapter 20: Pervasive Developmental Disorders and Psychoses  
*Nelson Essentials of Pediatrics* Elsevier, Philadelphia, PA, 2004, pp 81-103
3. **Scheffer, RE**: *Psychopharmacology: Clinical Implications of Brain Neurochemistry*. *Pediatric Clinics of North America* (2006) 53 (4): 767-776.
4. **Scheffer RE**: Omega 3 fatty acids, Complementary and Alternative Medicine in the Treatment of Pediatric Bipolar Disorder. Geller and DelBello Eds. (Chapter 8)
5. **Scheffer, RE**: *Psychiatric Disorders: Section IV:*  
 Chapter 16: Somatoform Disorders pg 63-67  
 Chapter 17: Anxiety and Phobias pg 67-72  
 Chapter 18: Depression and Bipolar Disorder pg 72-77

Chapter 19: Obsessive-Compulsive Disorder pg 76-77  
Chapter 20: Pervasive Developmental Disorders and Psychoses pg 77-80  
Nelson Essentials of Pediatrics Elsevier, Philadelphia, PA, 2009, pp 63-80

6. **Scheffer, RE:** Psychiatric Disorders: Section IV:  
Chapter 16: Somatoform Disorders pg  
Chapter 17: Anxiety and Phobias pg  
Chapter 18: Depression and Bipolar Disorder pg  
Chapter 19: Obsessive-Compulsive Disorder pg  
Chapter 20: Pervasive Developmental Disorders and Psychoses pg  
Nelson Essentials of Pediatrics Elsevier, Philadelphia, PA, 2013 (in press), pp

### **Editorials, Letters to Editor, Other**

1. **Scheffer RE,** Kowatch RA, Carmody T, Rush AJ: Letter to the Editor: In Response: A Randomized Placebo-Controlled Trial of Adderall for Symptoms of Comorbid ADHD in Pediatric Bipolar Disorder Following Mood Stabilization with Divalproex Sodium. Am. J. Psych. Nov 2005; 162: 2197 - 2198.
2. **Scheffer RE:** Treating Pediatric Psychiatric Illness With Selective Serotonin Reuptake Inhibitors. The Wisconsin Psychiatrist. (2006) 46(1): 21.
3. **Scheffer RE:** Childhood Onset Bipolar Disorder: A Role for Early Recognition and Treatment. J Pediatrics 150 (5): 459-460.

### **Publications Submitted Or In Preparation:**

1. Scheffer RE, Apps JN: A Randomized Controlled Trial of Adjunctive Topiramate for Treatment Resistant Pediatric Bipolar Disorder with Open Label Follow up.
2. Scheffer RE: Treatment Resistant Pediatric Bipolar Disorder: Fact or Myth.
3. Scheffer RE: Open Label Adjunctive Zonisamide for Treatment Resistant Pediatric Bipolar Disorder.
4. Scheffer RE: Early Behavioral Disinhibition with Divalproex Does not Predict Treatment Resistance.
5. Scheffer RE: The Evolution of Tardive Dyskinesia Early in the Course of Treatment with Aripiprazole.
6. Kowatch RA, Findling R, Scheffer RE: A Double-Blind Placebo Controlled Trial of Lithium and Divalproex for the Treatment of Pediatric Bipolar Disorder
7. Scheffer RE, Kowatch RA, Findling R: Polycystic Ovary Syndrome and Divalproex in Pediatric Bipolar Disorder
8. Scheffer RE: Clinical Implications of Pharmacogenomics for Child Psychiatrists. Current Psychiatry.
9. **Scheffer RE:** Clinical recognition of bipolar disorder symptoms in preschool children. J. Child and Adol Psychopharmacology (submitted).
10. **Collaborative Lithium Trial.**
11. Pediatric Bipolar Collaborative Trial.

---

Russell E. Scheffer, M.D.